The reason for this difference is likely to be found in the profile of the immune response elicited in each group; peripheral infection with ZIKV induces potent nAbs (which has been proven efficient in viral control), while the Ad-liNS1/NS2 vaccine induces non-neutralizing anti-NS1 antibodies and a polyfunctional CD8 T cell response. The gene discussed is LINS1; the disease is infection.